Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG vaccination to prevent serious respiratory tract infection and COVID-19 in vulnerable elderly
2020-003470-47Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of bcg vaccine in coronavirus disease 2019 (COVID-19) and Airways Infection (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Adaptive primary endpoint: COVID-19 and Adaptive primary endpoint: clinically relevant respiratory tract infection requiring medical intervention. Started Sep 2020; status: completed.
02
Drugs
bcg vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)Airways Infection
Beyond the preview
Go deeper on 2020-003470-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003470-47.